Shamburg News · 8-K filed Nov 12, 2026, 4:17 PM EST
ProMIS Neurosciences Reports Q3 2026 Results; Appoints Ivana Rubino Chief Commercial Officer
PMN · ProMIS Neurosciences Inc.
- Earnings
- Leadership change
- Materiality: high
ProMIS Neurosciences Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $8.2 million, or $(0.89) per basic and diluted share, compared with a net loss of $11.6 million, or $(5.93) per share, a year earlier. Cash was $44.1 million as of September 30, 2026, which the Company expects to fund operations through 2027. The release also reaffirmed that unblinded 12-month topline data from the PRECISE-AD Phase 1b trial are expected in the first quarter of 2027 and disclosed the appointment of Ivana Rubino, Ph.D., as Chief Commercial Officer effective October 5, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-126260.
Written from the filing by Shamburg Markets. Figures are as reported by the company.